|
Originally published In Press as doi:10.1074/jbc.M203682200 on May 24, 2002
J. Biol. Chem., Vol. 277, Issue 31, 27935-27944, August 2, 2002
Accessory Elements, Flanking DNA Sequence, and Promoter Context
Play Key Roles in Determining the Efficacy of Insulin and Phorbol Ester
Signaling through the Malic Enzyme and Collagenase-1 AP-1 Motifs*
Julio E.
Ayala ,
Ryan S.
Streeper ,
Christina A.
Svitek,
Joshua
K.
Goldman,
James K.
Oeser, and
Richard M.
O'Brien§
From the Department of Molecular Physiology and Biophysics,
Vanderbilt University Medical School, Nashville, Tennessee 37232
Received for publication, April 16, 2002, and in revised form, May 20, 2002
 |
ABSTRACT |
Insulin stimulates malic enzyme
(ME)-chloramphenicol acetyltransferase (CAT) and collagenase-1-CAT
fusion gene expression in H4IIE cells through identical activator
protein-1 (AP-1) motifs. In contrast, insulin and phorbol esters only
stimulate collagenase-1-CAT and not ME-CAT fusion gene expression in
HeLa cells. The experiments in this article were designed to explore
the molecular basis for this differential cell type- and gene-specific
regulation. The results highlight the influence of three variables,
namely promoter context, AP-1 flanking sequence, and accessory elements
that modulate insulin and phorbol ester signaling through the AP-1
motif. Thus, fusion gene transfection and proteolytic clipping gel
retardation assays suggest that the AP-1 flanking sequence affects the
conformation of AP-1 binding to the collagenase-1 and ME AP-1 motifs
such that it selectively binds the latter in a fully activated state.
However, this influence of ME AP-1 flanking sequence is dependent on
promoter context. Thus, the ME AP-1 motif will mediate both an insulin and phorbol ester response in HeLa cells when introduced into either
the collagenase-1 promoter or a specific heterologous promoter. But
even in the context of the collagenase-1 promoter, the effects of both
insulin and phorbol esters, mediated through the ME AP-1 motif are
dependent on accessory factors.
 |
INTRODUCTION |
Insulin regulates the transcription of more than 100 genes
indicating that this represents a major action of this hormone (1, 2).
The stimulatory and inhibitory effects of insulin on gene transcription
are mediated through various cis-acting elements
collectively referred to as insulin response sequences or elements
(IRSs/IREs).1 Unlike cAMP,
which regulates gene transcription predominantly through one
cis-acting element (3), a single consensus IRS does not
exist. Instead, six, distinct consensus IRSs have currently been well
defined (2) in addition to several IRSs that appear to be unique to
individual genes (1). Thus, this situation resembles that for phorbol
esters, which are able to regulate gene transcription through at least
eight distinct consensus sequences (4).
One of these consensus IRSs has the sequence T(G/A)TTT(T/G)(G/T) and
mediates the inhibitory effect of insulin on phosphoenolpyruvate carboxykinase, insulin-like growth factor binding protein-1,
apolipoprotein CIII, and glucose-6-phosphatase catalytic subunit gene
transcription (1, 2). The transcription factor FKHR binds this IRS but whether it mediates the action of insulin through this motif is unclear
(5-7). The other five consensus IRSs all mediate stimulatory effects
of insulin on gene transcription. They are the activator protein-1
(AP-1) motif, the serum response element (SRE), the Ets motif, the
thyroid transcription factor-2 motif, and the sterol response
element-binding protein (SREBP) motif (1, 2). Multiple hormones other
than insulin regulate gene expression through the AP-1 motif, the SRE,
and the Ets motif (8-10). In contrast, the thyroid transcription
factor-2 motif has currently only been shown to mediate effects of
insulin, cAMP (11), and cytokines (12) on thyroid gene expression.
Insulin and thyrotropin, the latter acting through cAMP, both stimulate
the expression of thyroid transcription factor-2 (11), which
contributes to the induction of thyroglobulin and thyroperoxidase gene
transcription by these hormones (1, 2). Similarly, insulin and cAMP
both regulate the expression of SREBP-1c, although in this case their
effects are antagonistic (13).
The AP-1 motif binds members of the Fos (c-Fos, FosB, Fra-1, and Fra-2)
and Jun (c-Jun, JunB, and JunD) transcription factor families (8) and
mediates the action of insulin on the expression of the hepatitis B
virus X gene and the genes encoding collagenase-1 (henceforth referred
to simply as collagenase) and malic enzyme (ME) (14-18). The mechanism
of insulin signaling through the AP-1 motif is poorly understood but
appears to involve effects of insulin on both the phosphorylation state
and mass of the AP-1 complex (1, 2). Thus, the potential exists for
insulin to have both short and long term effects on gene expression
through the same element. However, the mechanism of insulin signaling
appears to vary with the cell type studied (14, 16, 17, 19). For example, the stimulation of Fra-1 gene expression by insulin is seen in
some (19, 20), although not in all cell types (21) and the
protein kinases JNK1 and JNK2, which phosphorylate and activate c-Jun
(8), are only activated by insulin in some cell types (22) and not
others (19).
We have previously shown that, whereas insulin stimulates
collagenase-CAT and ME-CAT fusion gene expression in H4IIE cells, insulin only stimulates collagenase-CAT and not ME-CAT fusion gene
expression in HeLa cells (16, 17). In addition, phorbol esters
stimulate collagenase-CAT but not ME-CAT fusion gene expression in HeLa
cells (16). The experiments in this article were designed to explore
the molecular basis for: (i) the differential regulation of collagenase
and ME gene expression by insulin and phorbol esters in HeLa
cells and (ii) the differential regulation of ME gene expression by insulin in H4IIE and HeLa cells. The results highlight the influence of three additional variables, namely promoter context, AP-1 flanking sequence, and accessory elements that modulate insulin signaling through the AP-1 motif.
 |
EXPERIMENTAL PROCEDURES |
Materials--
[ -32P]dATP (>3000 Ci
mmol 1) and [3H]acetic acid, sodium salt
(>10 Ci mmol 1), were obtained from Amersham Biosciences
and ICN, respectively. Insulin was purchased from Collaborative
Bioproducts. Phorbol 12-myristate 13-acetate (PMA) was obtained from
Sigma. All oligonucleotides were synthesized by the Vanderbilt
University Medical Center Diabetes Core laboratory.
Plasmid Construction--
The construction of a collagenase-CAT
plasmid, containing the wild-type human collagenase promoter sequence
from 158 to +64, has been previously described (17). The TKCAT
plasmid contains the herpes simplex virus-thymidine kinase (TK)
promoter sequence from 105 to +51 ligated to the CAT reporter gene
and has a unique BamHI site in the polylinker at 105 (23).
The TKC-VI plasmid contains the herpes simplex virus-TK promoter
sequence from 480 to +51 ligated to the CAT gene and has a unique
BamHI linker between positions 40 and 35 (24). Various
double-stranded complementary oligonucleotides, representing distinct
regions of the ME or collagenase promoters (Table I), were synthesized
with BamHI compatible ends and were ligated in multiple
copies into BamHI-cleaved TK-CAT or as single copies, in
either the same or inverted orientation relative to that in the
endogenous gene, into BamHI-cleaved TKC-VI. Ligation of a
single copy of the ME or collagenase AP-1 motifs into the
BamHI site of TKC-VI fails to confer a phorbol ester response (data not shown). Plasmid XMB contains a minimal
Xenopus 68-kDa albumin promoter ligated to the CAT reporter
gene and has a unique HindIII site in the polylinker (17).
Double-stranded complementary oligonucleotides, representing various
regions of the ME or collagenase promoters (Table I), were synthesized
with HindIII compatible ends and ligated into
HindIII-cleaved XMB in multiple copies. The orientation and
number of inserts in the TKCAT, TKC-VI, and XMB plasmid constructs were
determined by restriction enzyme analysis and confirmed by DNA sequencing.
A previously described three-step PCR strategy (25, 26) was used to
switch the collagenase AP-1 flanking sequence to that of the ME AP-1
motif in the context of the collagenase promoter. The resulting
construct, designated Coll 158:ME (Fig. 8), was generated within the
context of the 158 to +64 collagenase promoter fragment. Briefly, two
complementary PCR primers were designed; the sequence of the sense
strand oligonucleotide was as follows (mutated nucleotides are
underlined):
5'-CAAGAGGATGTTATCCGCCGTGAGTCAGCGAGCCTCTGGCTTTC-3'. The AP-1 core sequence was unchanged and is shown in italics. This sense strand oligonucleotide was used in conjunction with a 3' PCR
primer to generate the 3'-half of the collagenase promoter, whereas the
complementary antisense strand oligonucleotide was used in conjunction
with a 5' PCR primer to generate the 5'-half of the collagenase
promoter. These 5' and 3' primers were designed to maintain the 5' and
3' junctions of the collagenase promoter fragments to be the same as
that in the wild-type 158 to +64 collagenase-CAT fusion gene
construct. The PCR products from these two reactions were then combined
and used themselves as both primer and template in a second PCR
reaction to generate a small amount of the full-length, mutated
collagenase promoter fragment. Finally, the 5' and 3' PCR primers were
then used to amplify this fragment. An identical strategy was used to
generate a promoter fragment in which the orientation of the ME AP-1
motif in the context of the Coll 158:ME construct was switched by
changing the core sequence from TGAGTCA to TGACTCA. Truncated
constructs, designated Coll 79 and Coll 79:ME (Fig. 8), were then
generated using the same 3' PCR primer described above and the
following 5' PCR primers, respectively:
5'-CCGCTCGAGAAAGCATGAGTCAGACAG-3';
5'-CCGCTCGAGCCGCCGTGACTCAGCGAGCCTCTGGCTTTCTGG-3' (AP-1 core sequences are shown in italics and XhoI
cloning sites are underlined). All promoter fragments were completely
sequenced to ensure the absence of polymerase errors and plasmids were
purified by centrifugation through cesium chloride gradients (27).
Cell Culture and Transient Transfection--
Rat H4IIE hepatoma
cells were grown to 40-70% confluence in T150 flasks in Dulbecco's
modified Eagle's medium containing 2.5% (v/v) fetal calf serum and
2.5% (v/v) newborn calf serum and were transiently transfected using
the calcium phosphate-DNA co-precipitation method as previously
described (16). Transfected cells were incubated for 20 h in
serum-free Dulbecco's modified Eagle's medium prior to harvesting.
Human HeLa cervical carcinoma cells were grown to 90% confluence in
T150 flasks in Dulbecco's modified Eagle's medium containing 10%
(v/v) calf serum and were replated the day before use into 55-cm2 culture dishes. Attached cells were then transiently
transfected using the calcium phosphate-DNA co-precipitation method as
previously described (16). In some experiments (Figs. 6 and 8) the
reporter gene construct (15 µg) and an expression vector for
-galactosidase (2.5 µg) were co-transfected with an expression
vector encoding the insulin receptor (5 µg), courtesy of Dr. Jonathan
Whittaker. After an overnight incubation the medium was replaced
with serum-free Dulbecco's modified Eagle's medium supplemented,
where indicated in the figure legends, with or without 100 nM PMA or 100 nM insulin. The cells were then
incubated for a further 20 h prior to harvesting. For the analysis
of basal gene expression, three independent preparations of each
plasmid construct were analyzed in duplicate.
CAT and -Galactosidase Assays--
Transfected HeLa and H4IIE
cells were harvested by trypsin digestion and then sonicated in 300 µl of 250 mM Tris (pH 7.8) containing 2 mM
phenylmethylsulfonyl fluoride. The HeLa cell lysate was assayed for
-galactosidase activity as previously described (16). The remaining
HeLa cell lysate and the H4IIE lysate were heated for 10 min at
65 °C and cellular debris was removed by centrifugation. CAT assays
were then performed on the supernatant as previously described (16). To
correct for variations in HeLa cell transfection efficiency, the
results were expressed as the ratio of CAT: -galactosidase activity.
In earlier studies we had found that phorbol esters and insulin
stimulated Rous sarcoma virus- -galactosidase expression in
HeLa cells (16) but that was not apparent in this series of
experiments. To correct for variations in H4IIE cell transfection
efficiency, CAT activity was corrected for the protein concentration in
the cell lysate, as measured by the Pierce BCA assay.
Gel Retardation Assays--
To study AP-1 binding, the
preparation of HeLa cell nuclear extracts, the labeling of
double-stranded oligonucleotide probes, and gel retardation assays were
performed under conditions exactly as previously described (16, 28).
Gel retardation competition experiments and partial proteolytic
clipping bandshift assays were also performed as previously described
(16).
 |
RESULTS |
The ME AP-1 Motif Markedly Enhances Basal Fusion Gene Transcription
in Both HeLa and H4IIE Cells--
We have previously shown that
insulin stimulates collagenase-CAT and ME-CAT fusion gene expression in
H4IIE cells but insulin only stimulates collagenase-CAT and not ME-CAT
fusion gene expression in HeLa cells (16, 17). In addition, we found
that phorbol esters stimulate collagenase-CAT but not ME-CAT fusion
gene expression in HeLa cells (16). We previously suggested that these
results may be explained, in part, by the observation that the ME and collagenase AP-1 motifs are functionally distinct (16). Thus, transient
transfection experiments in HeLa cells using heterologous TKCAT fusion
genes showed that AP-1 binds the ME AP-1 motif, but not the collagenase
AP-1 motif, in an activated state. As a consequence, only the
collagenase AP-1 motif confers an additional stimulatory effect of
phorbol esters on the expression of a heterologous TKCAT fusion gene
(16). In these experiments multiple copies of a double stranded
oligonucleotide representing the ME AP-1 motif were ligated into the
polylinker of a heterologous TKCAT fusion gene and this resulted in a
marked increase in basal fusion gene expression, relative to that
obtained with the basic TKCAT vector alone (16). This marked increase
in basal fusion gene expression was selectively seen with the ME AP-1
motif because ligation of multiple copies of a double stranded
oligonucleotide representing the collagenase AP-1 motif into the TKCAT
polylinker resulted in only a small increase in basal fusion gene
expression (16). In contrast, when multiple copies of a double stranded
oligonucleotide representing a mutated ME AP-1 motif, which fails to
bind AP-1 in gel retardation assays, were ligated into the TKCAT
polylinker there was no increase in basal fusion gene expression,
relative to that obtained with the basic TKCAT vector alone
(16).
To extend these observations, we first determined whether the marked
stimulation of basal fusion gene expression by the ME AP-1 motif was
specific to the context of the heterologous TKCAT fusion gene.
Therefore, experiments similar to those described above were repeated
using a different heterologous fusion gene, designated TKC-VI (24). The
TKCAT vector contains the herpes simplex virus TK promoter sequence
from 105 to +51 ligated to the CAT reporter gene and has a unique
BamHI site in the polylinker at 105 (23). By contrast, the
TKC-VI plasmid contains the herpes simplex virus-TK promoter sequence
from 480 to +51 ligated to the CAT gene and has a unique
BamHI linker between positions 40 and 35 (24). Various
double stranded oligonucleotides representing distinct regions of the
ME or collagenase promoters (Table I) were synthesized with BamHI compatible ends and were ligated
as single copies, in the same orientation as that found in the
endogenous ME and collagenase promoters, into BamHI-cleaved
TKC-VI. Typically, a maximal oligonucleotide size of 42 bp can be
cloned into the BamHI site of the TKC-VI vector without
losing basal reporter gene expression (24), therefore, multimerized
AP-1 motifs were not analyzed in this vector context. The level of
reporter gene expression directed by the resulting constructs was then
analyzed by transient transfection of HeLa cells (Fig.
1A).
View this table:
[in this window]
[in a new window]
|
Table I
Sequence of oligonucleotides used in these studies
All nucleotide positions are negative and are numbered relative to the
transcription start site at +1. The consensus Sp1, Efr-1, and AP-1
motifs are boxed. Non-wild-type sequence is shown in lower case
letters. WT, wild-type; MUT,
mutant.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 1.
The ME AP-1 motif markedly enhances basal
TKC-VI gene transcription in both HeLa and H4IIE cells. HeLa
(panel A) and H4IIE cells (panel B) were
transiently transfected, as described under "Experimental
Procedures," with various TKC-VI fusion gene plasmids. In addition,
HeLa cells were co-transfected with an expression vector encoding
-galactosidase. The fusion gene plasmids represented either the
basic TKC-VI vector or constructs in which a single copy of
oligonucleotides representing the indicated wild-type (WT)
ME or collagenase (Coll) promoter sequences, as shown in
Table I, had been ligated into the BamHI site of the TKC-VI
promoter in the same orientation as that in the native ME and
collagenase promoters. Following transfection cells were incubated for
20 h in serum-free medium. Cells were then harvested and CAT
activity, -galactosidase activity, and protein concentration were
assayed as previously described (16, 17). The results are expressed as
the ratio of CAT: -galactosidase activity, in HeLa cell
transfections, or CAT:protein concentration, in H4IIE cell
transfections. Results represent the mean ± S.E. of three
experiments, using an independent preparation of each plasmid
construct, in which each construct was assayed in duplicate.
|
|
Oligonucleotides representing the ME promoter sequence between 161
and 123, between 138 and 101, and between 138 and 123, all of
which contain the ME AP-1 motif (Table I), all conferred a marked
increase in basal fusion gene expression, relative to that obtained
with the basic TKC-VI vector alone (Fig. 1A). In contrast,
the oligonucleotide representing the collagenase AP-1 motif did not
confer an increase in basal fusion gene expression (Fig.
1A). This result indicates that the activation of basal fusion gene expression by the ME AP-1 motif was not specific to the
context of the TKCAT vector and, in addition, demonstrates that this
effect does not require multimerization of the ME AP-1 motif. This
result also raises the possibility that the slight activation of basal
fusion gene expression by the collagenase AP-1 motif in the context of
the TKCAT vector (16) may require the multimerization of this motif.
Next, to determine whether the activation of basal fusion gene
expression by the ME AP-1 motif was specific to HeLa cells, the plasmid
constructs described above were transiently transfected into rat
hepatoma H4IIE cells. As shown in Fig. 1B, similar results were also obtained in the H4IIE cell line. Thus, the ME AP-1 motif, but
not the collagenase AP-1 motif, again stimulated a marked increase in
basal fusion gene expression, relative to that obtained with the basic
TKC-VI vector alone. Interestingly, an oligonucleotide representing the
ME promoter sequence between 181 and 145, which contains
overlapping Egr-1 and Sp protein-binding sites (Table I), only
conferred an increase in basal fusion gene expression in HeLa and not
H4IIE cells, relative to that obtained with the basic TKC-VI vector
alone (Fig. 1). The potential significance of this observation to cell
type-specific, insulin-stimulated ME gene expression is described under
"Discussion."
Mutation of the Flanking Sequence Either 5' or 3' of the ME AP-1
Motif Markedly Reduces the Enhancement of Basal TKC-VI Gene
Transcription in Both HeLa and H4IIE Cells without Affecting AP-1
Binding Affinity--
The selective activation of basal fusion gene
expression by the ME and not the collagenase AP-1 motif was surprising
because the AP-1 complex binding both the ME and collagenase AP-1
motifs in HeLa cells (16) and H4IIE cells (data not shown) is
predominantly a heterodimer of Fra-2 and JunD. However, partial
proteolytic clipping bandshift assays indicated that AP-1 binds the ME
and collagenase AP-1 motifs in distinct conformations so we postulated that this could explain the distinct functional characteristics of the
two AP-1 motifs (16). Surprisingly, the ME and collagenase AP-1 motifs
both share an identical core consensus sequence, TGACTCA (Table I).
However, the 5' and 3' sequences flanking the core are distinct (Table
I). To determine whether the distinct AP-1 flanking sequence could
explain the discrete functional characteristics of the ME and
collagenase AP-1 motifs, the effect of mutating this flanking sequence
was investigated.
Double stranded oligonucleotides representing the ME AP-1 motif but
containing mutations of the 5' (MUT1), core (MUT2), or 3'-flanking
sequence (MUT3) (Table I) were synthesized with BamHI compatible ends and were ligated as single copies into
BamHI-cleaved TKC-VI in either the same or the inverted
orientation relative to that found in the endogenous ME promoter. The
level of reporter gene expression directed by the resulting constructs
was then analyzed by transient transfection of HeLa (Fig.
2, A and C) and H4IIE (Fig. 2B) cells. Similar results were obtained in both
cell lines (compare Fig. 2, A and B) and with
both orientations of the ME and collagenase AP-1 motifs (compare Fig.
2, A and C). The MUT2 oligonucleotide that
contains a mutation of the core sequence of the ME AP-1 motif, which
abolishes binding of AP-1 in gel retardation assays (16) (Fig.
3), failed to confer an increase in basal
TKC-VI fusion gene expression (Fig. 2). Similarly, mutating the
3'-flanking sequence of the ME AP-1 motif resulted in markedly reduced
basal TKC-VI fusion gene expression compared with that conferred by the
wild-type ME AP-1 motif (Fig. 2). Similarly, mutation of the
5'-flanking sequence also reduced the activation of basal fusion gene
expression, although it was less deleterious than the 3'-flanking
sequence mutation (Fig. 2).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 2.
Mutation of the flanking sequence either 5'
or 3' of the ME AP-1 motif markedly reduces the enhancement of basal
TKC-VI gene transcription in both HeLa and H4IIE cells. HeLa
(panels A and C) and H4IIE cells (panel
B) were transiently transfected, as described under
"Experimental Procedures," with various TKC-VI fusion gene
plasmids. In addition, HeLa cells were co-transfected with an
expression vector encoding -galactosidase. The fusion gene plasmids
represented either the basic TKC-VI vector or constructs in which
oligonucleotides representing the indicated wild-type (WT)
or mutated (MUT) ME or collagenase promoter sequences, as
shown in Table I, had been ligated into the BamHI site of
the TKC-VI promoter in a single copy in either the same
(correct; panels A and B) or inverted
(panel C) orientation relative to that in the native ME and
collagenase promoters. Following transfection cells were incubated for
20 h in serum-free medium. Cells were then harvested and CAT
activity, -galactosidase activity, and protein concentration were
assayed as previously described (16, 17). The results are expressed as
the ratio of CAT: -galactosidase activity, in HeLa cell
transfections, or CAT/protein concentration, in H4IIE cell
transfections. Results represent the mean ± S.E. of three
experiments, using an independent preparation of each plasmid
construct, in which each construct was assayed in duplicate.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 3.
Mutation of the flanking sequence 5' or 3' of
the ME AP-1 motif does not affect the affinity of AP-1 binding.
Panel A, the labeled ME 138/123 WT oligonucleotide probe was
incubated in the absence ( ) or presence of a 100-fold molar excess of
the unlabeled oligonucleotide competitors shown (Table I) prior to
addition of HeLa cell nuclear extract. Protein binding was then
analyzed using the gel retardation assay as described under
"Experimental Procedures." In the representative autoradiograph
shown, only the retarded complexes are visible and not the free probe,
which was present in excess. A nonspecific (NS) protein-DNA
interaction is indicated by an arrow as is the AP-1 complex.
Panel B, the labeled ME 138/123 WT oligonucleotide probe was
incubated in the absence ( ) or presence of various concentrations of
the unlabeled ME 138/123 WT ( ), ME 138/123 MUT1 ( ), and ME
138/123 MUT3 ( ) oligonucleotide competitors prior to addition of
HeLa cell nuclear extract. Protein binding was then analyzed using the
gel retardation assay as described under "Experimental Procedures."
Protein binding was quantified by using a Packard Instant Imager to
count 32P associated with retarded complexes. The data
represents the mean ± S.D. of two experiments.
|
|
These results could potentially be explained by an effect of the
flanking sequence mutations on the affinity of AP-1 binding. To
investigate this possibility the oligonucleotides shown in Table I were
used as competitors, at a 100-fold molar excess, in a gel retardation
assay with the ME 138/123 WT oligonucleotide as the labeled probe (Fig.
3A). As expected, the wild-type collagenase AP-1 motif and
the oligonucleotides containing the wild-type ME AP-1 motif, namely ME
161/123 WT, ME 138/101 WT, and ME 138/123 WT, all competed effectively
against the labeled probe for formation of the AP-1 protein-DNA complex
(Fig. 3A). In contrast, the ME 181/145 WT oligonucleotide
that does not contain the ME AP-1 motif (Table I), and the ME 138/123
MUT2 oligonucleotide that contains a mutation of the AP-1 core sequence
(Table I), did not compete for AP-1 binding (Fig. 3A).
Importantly, the oligonucleotides containing the 5' or 3' ME AP-1
flanking sequence mutations, designated ME 138/123 MUT1 and MUT3,
respectively, both competed effectively against the labeled probe for
formation of the AP-1 protein-DNA complex when used at a 100-fold molar
excess (Fig. 3A). Moreover, competition experiments in which
the labeled ME 138/123 WT oligonucleotide was preincubated with various
concentrations of the unlabeled ME 138/123 WT, MUT1, and MUT3
oligonucleotides indicated that these mutations do not markedly affect
the affinity of AP-1 binding (Fig. 3B). Thus, all three
oligonucleotides competed equally effectively for formation of the AP-1
complex (Fig. 3B).
Mutation of the Flanking Sequence Either 5' or 3' of the ME AP-1
Motif Markedly Reduces the Enhancement of Basal TKCAT Gene
Transcription and Restores Phorbol Ester Responsiveness--
To
determine whether the effects of mutating the flanking sequence on
either side of the ME AP-1 motif were specific to the context of the
heterologous TKC-VI vector, experiments similar to those shown in Fig.
2 were repeated using the heterologous TKCAT vector. Multiple copies of
the double stranded oligonucleotides containing the various mutations
of the ME AP-1 motif described above were ligated into the polylinker
of the TKCAT vector. The level of reporter gene expression directed by
the resulting constructs in the presence and absence of a phorbol
ester, PMA, was then analyzed by transient transfection of HeLa
cells (Fig. 4).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
Mutation of the flanking sequence either 5'
or 3' of the ME AP-1 motif markedly reduces the enhancement of basal
TKCAT gene transcription and restores phorbol ester
responsiveness. HeLa cells were transiently co-transfected, as
described under "Experimental Procedures," with a -galactosidase
expression vector and either the basic TKCAT vector or constructs in
which oligonucleotides representing the indicated wild-type
(WT) or mutated (MUT) ME or collagenase
(Coll) promoter sequences, as shown in Table I, had been
ligated into the BamHI site of the TK promoter in multiple
(3-4) copies. Following transfection cells were incubated for 20 h in serum-free medium in the presence or absence of 100 nM
PMA. The cells were then harvested and both CAT and -galactosidase
activity were assayed as previously described (16, 17). In panel
A, results are presented as the relative ratio of
CAT: -galactosidase activity, in PMA-treated versus
control cells and are expressed as fold induction. In panels
B and C, results are presented as the ratio of
CAT: -galactosidase activity in either control or PMA-treated cells,
respectively, and are expressed as arbitary units. Results represent
the mean ± S.E. of five experiments, in which each construct was
assayed in duplicate.
|
|
Oligonucleotides representing the wild-type ME promoter sequence
between 161 and 123 or between 138 and 123, both of which encompass the ME AP-1 motif, both conferred a marked activation of
basal fusion gene expression (Fig. 4B) but neither
oligonucleotide was able to confer a stimulatory effect of PMA on
fusion gene expression beyond that seen with the basic TKCAT vector
(Fig. 4A). With the multimerized ME 138/123 WT
oligonucleotide the spacing between individual AP-1 motifs was similar
to that obtained with the multimerized collagenase 63/78 WT
oligonucleotide (Table I). The latter does confer a phorbol ester
response (Fig. 4A) but not an activation of basal fusion
gene expression (Fig. 4B). Thus, the inability of the longer
ME 161/123 WT oligonucleotide (Table I) to confer a phorbol ester
response was not indicative of an inability of the individual AP-1
motifs in the multimerized oligonucleotide to synergize because of
increased spacing between individual AP-1 sites.
As seen in the context of the TKC-VI vector, mutation of the 5'- or
3'-flanking sequence of the ME AP-1 motif reduced the activation of
basal TKCAT fusion gene expression, with mutation of the 3'-flanking
sequence again being more deleterious (Fig. 4B).
Importantly, in contrast to the wild-type ME AP-1 motif, these mutated
ME AP-1 motifs were now able to confer a stimulatory effect of phorbol
esters on fusion gene expression that was similar in magnitude, when
the data was expressed as fold induction, to that obtained with the
collagenase AP-1 motif (Fig. 4A). Fig. 4C shows
that the wild-type ME and collagenase AP-1 motifs conferred a similar
level of maximal, phorbol ester-stimulated fusion gene expression.
Thus, the level of phorbol ester-stimulated collagenase AP-1 TKCAT
fusion gene expression was similar to that of basal ME AP-1 TKCAT gene
expression. Whereas the mutated ME AP-1 motifs were able to confer a
stimulatory effect of phorbol esters on fusion gene expression (Fig.
4A) only the ME 5'-flanking mutant directs a maximal level
of CAT expression similar to that obtained with the wild-type ME and
collagenase AP-1 TKCAT fusion genes (Fig. 4C). This suggests
that even phorbol ester treatment was unable to fully activate AP-1
bound to the ME AP-1 3'-flanking mutant. Unfortunately, in HeLa cells,
unlike H4IIE cells (16), insulin markedly stimulates CAT expression
directed by the control TKCAT fusion gene (data not shown). Therefore,
it was not possible to determine whether insulin can also selectively
activate gene transcription through the collagenase but not the ME AP-1
motif, in the context of the TKCAT vector.
Mutation of the Flanking Sequence 5' or 3' of the ME AP-1 Motif
Affects the Conformation of AP-1 Binding--
The proteolytic band
shift assay (29) was used to examine the possibility that the ME AP-1
5'- and 3'-flanking mutations affected the conformation of AP-1
binding. As described above, we previously used this assay to
demonstrate that AP-1 bound to the wild-type collagenase and ME AP-1
motifs have different surfaces exposed to proteolytic digestion
indicative of a difference in binding conformation (16). This
difference in binding conformation was hypothesized to be the basis for
the selective activation of basal TKCAT fusion gene expression by the
ME AP-1 motif (16).
To study the effect of partial protease digestion, HeLa cell nuclear
extract was preincubated with the labeled collagenase 63/78 WT, ME
138/123 WT, ME 138/123 MUT1, or ME 138/123 MUT3 oligonucleotides (Table
I) prior to the addition of various concentrations of chymotrypsin
(Fig. 5). A distinct proteolytic product
that selectively binds the collagenase 63/78 WT, ME 138/123 MUT1, and
ME 138/123 MUT3 oligonucleotide probes but not the ME 138/123 WT
oligonucleotide probe was detected (Fig. 5, see arrow). This
selectively bound product migrates faster than a nonspecific
protein-DNA interaction detected in this assay (Fig. 5) so it was
possible that this product was derived from proteolysis of the
nonspecific protein-DNA interaction rather than the AP-1 complex.
However, competition experiments revealed that the unlabeled wild-type
collagenase 63/78 WT oligonucleotide competed effectively for the
formation of this protein-DNA complex (data not shown), whereas it does
not compete for formation of the nonspecific complex (Fig.
3A). This result demonstrates that the proteins bound to the
wild-type collagenase AP-1 motif and the ME AP-1 5'- and 3'-flanking
mutants have similar surfaces exposed to proteolytic digestion,
indicative of similar binding conformations. Thus, the ME AP-1 5'- and
3'-flanking mutants bind AP-1 in a conformation more similar to that of
AP-1 bound to the collagenase AP-1 motif rather than AP-1 bound to the
wild-type ME AP-1 motif. These observations could explain why the
oligonucleotides containing the ME AP-1 5'- or 3'-flanking mutations,
just like the collagenase AP-1 motif, do not enhance basal TKC-VI (Fig. 2) or TKCAT (Fig. 4) fusion gene expression, but do mediate a phorbol
ester response (Fig. 4).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 5.
Mutation of the flanking sequence 5' or 3' of
the ME AP-1 motif affects the conformation of AP-1 binding. HeLa
cell nuclear extract from control cells was incubated with the labeled
ME 138/123 WT (ME WT), ME 138/123 MUT1 (MUT1), ME 138/123 MUT3 (MUT3),
or collagenase 63/78 WT (Coll) oligonucleotide probes for 10 min at
room temperature prior to the addition of various amounts of
chymotrypsin and incubation for an additional 2 min at room
temperature. Protein binding was then analyzed using the gel
retardation assay as described under "Experimental Procedures." In
the representative autoradiograph shown, only the retarded complexes
are visible and not the free probe, which was present in excess. A
nonspecific (NS) protein-DNA interaction is indicated by an
arrow, as are the AP-1 complex and a proteolytic fragment
that specifically binds the Coll, MUT1, and MUT3 probes but not the
MEOV probe.
|
|
The Wild-type ME AP-1 Motif Can Confer a Stimulatory Effect of
Insulin and Phorbol Esters on the Expression of a Heterologous Xenopus
Albumin-CAT Fusion Gene--
The basic heterologous TKC-VI (Fig. 1)
and TKCAT (Fig. 4) vectors both direct a high level of basal CAT
expression, even without the ME AP-1 motif ligated into their
respective polylinkers. In contrast, a heterologous Xenopus
albumin-CAT fusion gene, designated XMB, has previously been shown to
direct no basal CAT expression in HeLa cells (17). The ME and
collagenase AP-1 motifs were therefore ligated into the polylinker of
the XMB vector to determine whether, in this context, the functional
characteristics of the two AP-1 motifs would be distinct. Fig.
6 shows that, in the context of the XMB
vector, the ME AP-1 motif still confers a greater increase in basal
fusion gene expression than the collagenase AP-1 motif. However, in
this context, both the ME and collagenase AP-1 motifs can mediate both
a phorbol ester (Fig. 6A) and insulin (Fig. 6B) response in HeLa cells. When ligated into the XMB polylinker, oligonucleotides containing mutations of the ME or collagenase AP-1
motifs (Table I), which abolish AP-1 binding (16, 17), fail to confer
basal reporter gene expression or an increase in expression in the
presence of insulin or phorbol esters (Fig. 6). Thus, this result
suggests that the inability of insulin to induce ME-CAT gene expression
in HeLa cells, in contrast to H4IIE cells, was because of some cell
type-specific feature relating to the specific context of the ME
promoter and not a difference in the insulin signaling pathway in these
two cell lines. Similarly, this result further suggests that the
inability of phorbol esters to induce ME-CAT gene expression in HeLa
cells was also because of the same issue of ME promoter context.
Indeed, both insulin and phorbol esters induce AP-1 binding to both the
collagenase and ME AP-1 motifs in HeLa cells (Fig.
7). In summary, the data in Figs. 4 and 6
suggest that the functional characteristics of the ME and collagenase
AP-1 motifs, with respect to basal activation and insulin/phorbol ester
responsiveness, are determined by both flanking sequence and promoter
context.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 6.
The wild-type ME AP-1 motif can confer a
stimulatory effect of insulin and phorbol esters on the expression of a
heterologous Xenopus albumin-CAT fusion gene.
HeLa cells were transiently co-transfected, as described under
"Experimental Procedures," with various XMB fusion gene plasmids
and an expression vector encoding -galactosidase. The fusion gene
plasmids represented either the basic XMB vector or constructs in which
oligonucleotides representing either the wild-type (WT) or
mutated (MUT) ME or collagenase (Coll) promoter
sequence from 138 to 123 and 63 to 78, respectively, as shown
in Table I, had been ligated into the HindIII site of the
Xenopus albumin promoter in multiple (4 to 5) copies.
Following transfection cells were incubated for 20 h in serum-free
medium in the absence (C) or presence of 100 nM
PMA (P) or 100 nM insulin (I). Cells
were then harvested and CAT and -galactosidase activity were assayed
as previously described (16, 17). The results are expressed as the
ratio of CAT: -galactosidase activity and represent the mean ± S.E. of six experiments, in which each construct was assayed in
duplicate.
|
|

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 7.
Insulin and phorbol esters stimulate protein
binding to both the collagenase and ME AP-1 motifs. Nuclear
extracts were prepared from HeLa cells incubated for 5 h in
serum-free medium (C) or serum-free medium
supplemented with either 100 nM insulin (I) or
100 nM PMA (P). Protein binding to the labeled
ME 138/123 and collagenase (Coll) 63/78 oligonucleotide
probes was then analyzed using the gel retardation assay, as described
under "Experimental Procedures." In the representative
autoradiograph shown, only the retarded complexes are visible and not
the free probe, which was present in excess. A nonspecific
(NS) protein-DNA interaction and the AP-1 complex are
indicated by the arrows.
|
|
The ME AP-1 Motif Can Mediate an Insulin and Phorbol Ester Response
in the Context of the Collagenase Promoter--
Because the
multimerized ME AP-1 motif was able to mediate both an insulin and
phorbol ester response in the context of the heterologous XMB vector
(Fig. 6) the molecular basis for the inability of insulin and phorbol
esters to stimulate the activity of the native ME promoter in HeLa
cells was further investigated. Fry and Farnham (30) recently reviewed
various aspects of promoter context that are important in the
regulation of gene transcription, one of which are the presence of
accessory elements. We have previously shown that the stimulatory
effects of insulin and phorbol esters on collagenase-CAT fusion gene
expression are markedly enhanced by accessory elements in the
collagenase promoter (17). Expression of a truncated collagenase fusion
gene construct that contains the AP-1 motif but lacks these accessory
elements was minimally induced by insulin and phorbol esters (17). We
therefore speculated that perhaps the ME promoter lacks accessory
elements that could enhance insulin and phorbol ester signaling through
the ME AP-1 motif in HeLa cells.
To indirectly address this potential role for the absence of accessory
elements in the ME promoter, a collagenase-CAT fusion gene was
generated in which the flanking sequence of the collagenase AP-1 motif
was replaced with that of the ME AP-1 motif in the context of a
collagenase promoter fragment with a 5' end point of 158. This
fragment contains the accessory elements necessary for full induction
of gene expression by insulin and phorbol esters (17). This strategy
allowed us to ask the question as to whether the ME AP-1 motif could
mediate an insulin and phorbol ester response if it were associated
with accessory elements and located in the same context as the
collagenase AP-1 motif. The effects of insulin and phorbol esters on
the expression of this fusion gene, designated Coll 158:ME, were
assessed by transient transfection of HeLa cells (Fig.
8).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 8.
The ME AP-1 motif can mediate an insulin and
phorbol ester response in the context of the collagenase promoter.
HeLa cells were transiently co-transfected, as described under
"Experimental Procedures," with an expression vector encoding
-galactosidase and either collagenase-CAT fusion genes with 5'
deletion end points of 158 or 79, designated Coll 158 and Coll 79, respectively, or constructs, designated Coll 158:ME and Coll 79:ME, in
which the collagenase AP-1 flanking sequence was replaced with that of
the ME AP-1 motif within the context of the 158 or 79 end points,
respectively. Following transfection cells were incubated for 20 h
in serum-free medium in the absence or presence of 100 nM
PMA or 100 nM insulin. Cells were then harvested and CAT
and -galactosidase activity were assayed as previously described
(16, 17). The ratio of CAT: -galactosidase activity in control cells
(panel A) and the relative ratio of CAT: -galactosidase
activity in insulin-treated cells (panel B) or phorbol
ester-treated cells (panel C) versus control
cells were then calculated. The mean induction of Coll 158 expression
by insulin and phorbol ester was ~14- and 43-fold, respectively. The
results are presented as a percentage relative to the 158 Coll fusion
gene and represent the mean ± S.E. of three to seven experiments,
using several independent preparations of each plasmid construct, in
which each construct was assayed in duplicate.
|
|
One possible outcome of this experiment was that the ME AP-1 motif
could have maximally activated basal collagenase-CAT fusion gene
expression such that no effect of insulin and phorbol esters would be
seen despite the presence of accessory elements. But in fact the data
shows that the presence of the ME AP-1 motif in the collagenase
promoter actually led to a decrease in basal fusion gene expression
(Fig. 8A), and in this context the ME AP-1 motif was able to
confer a similar induction of fusion gene expression by insulin (Fig.
8B) and phorbol esters (Fig. 8C) as obtained with
the native collagenase AP-1 motif. Changing the orientation of the ME
AP-1 motif in the context of the Coll 158:ME construct (Fig. 8) by
switching the core sequence from TGAGTCA to TGACTCA had no effect on
basal expression or the magnitude of the insulin and phorbol ester
response (data not shown).
When the accessory elements in the Coll 158 or Coll 158:ME fusion genes
were deleted, the truncated collagenase promoter constructs, designated
Coll 79 and Coll 79:ME, respectively, mediated a minimal induction of
collagenase-CAT fusion gene expression by insulin and phorbol esters
(Fig. 8). These results suggest that the absence of accessory elements
in the ME promoter may partly account for the inability of insulin and
phorbol esters to induce ME-CAT fusion gene expression in HeLa cells.
 |
DISCUSSION |
The experiments in this article were designed to explore the
molecular basis for: (i) the differential regulation of
collagenase-1 and ME gene expression by insulin
and phorbol esters in HeLa cells and (ii) the differential regulation
of ME gene expression by insulin in H4IIE and HeLa cells. We
hypothesize that the former is partly explained by the observation that
the ME and collagenase AP-1 motifs are functionally distinct (16).
Thus, AP-1 can bind the ME AP-1 motif, but not the collagenase AP-1
motif in an activated state and, in a heterologous context, this
precludes further activation by phorbol esters. This observation was
surprising because both motifs share an identical core consensus
sequence (Table I) and predominantly bind a heterodimer of Fra-2 and
JunD (16) with similar affinities (Fig. 3). We show here that this
binding of AP-1 to the ME AP-1 motif in an activated state is
determined by the specific sequence flanking the core AP-1 motif (Figs.
2 and 4). Phorbol ester-insensitive AP-1 motifs have also been
identified in the stromelysin (31), JE (32), and
glutathione S-transferase P1-1 promoters (33, 34) and it has
also been previously shown that the sequence flanking the core AP-1
motif can influence phorbol ester responsiveness (35, 36). However,
this has been attributed to changes in the affinity of AP-1 binding
and/or the composition of the AP-1 complex (32, 37). The ME promoter is
therefore distinct in that neither of the latter parameters differs in
comparison with the phorbol ester-sensitive collagenase AP-1 motif
(Fig. 3) (16). Instead, the flanking sequence of the ME AP-1 motif appears to affect phorbol ester responsiveness by altering the conformation of AP-1 binding (Fig. 5). Thus, these studies on the ME
AP-1 motif are consistent with the emerging realization that hormone
response elements are not inert but can act as allosteric regulators by
affecting the conformation of the factors they bind (38).
The specific functional characteristics of the ME AP-1 motif are also
affected by promoter context. Thus, when ligated to the heterologous
XMB promoter, even though the ME AP-1 motif stimulates basal fusion
gene expression, it does not do so sufficiently to prevent a further
induction by phorbol esters and insulin (Fig. 6). Similarly, when
switched with the collagenase AP-1 motif in the collagenase promoter,
the ME AP-1 motif can again mediate both an insulin and phorbol ester
response in HeLa cells (Fig. 8). The specific
context-dependent features of the XMB promoter that allow
for insulin- and phorbol ester-dependent activation of the
ME AP-1 motif are unclear. However, in the collagenase promoter, one
critical context-dependent characteristic is the presence
of accessory elements; the effects of insulin and phorbol esters are
markedly reduced if these accessory elements are deleted (17) (Fig. 8).
It is possible that the differential regulation of ME gene expression
by insulin in H4IIE and HeLa cells may also, in part, reflect the
importance of an accessory element. We have previously shown that, in
H4IIE cells, an accessory element, located between 180 and 152,
enhances insulin signaling through the ME AP-1 motif (16). This region
of the ME promoter contains overlapping binding sites for Egr-1 and Sp
proteins (Table I), however, using nuclear extract prepared by the
method of Shapiro et al. (28), only the insulin-induced
binding of Egr-1 was detected; we therefore proposed that Egr-1 was the
accessory factor binding this element (16). Using nuclear extract
prepared by the method of Andrews and Faller (39), modified by the
incorporation of Nonidet P-40 to lyse cells and isolate nuclei (40),
the insulin-induced binding of both Egr-1 and Sp factors to this
accessory element can be
demonstrated.2 Gel
retardation assays reveal an inverse relationship between the abundance
of insulin-induced Egr-1 and Sp proteins in H4IIE and HeLa cells with
Egr-1 more abundant than Sp proteins in the former.2
Therefore, we hypothesize that the selective regulation of ME gene
expression in H4IIE and HeLa cells may be explained, at least in
part, by the differential binding of these factors to the same accessory element in the ME promoter in the two cell types.
Competition between Egr-1 and Sp proteins for overlapping binding sites
is known to be important in the regulated expression of other genes
(41). Barroso and Santisteban (18) have shown that Egr-1 competes for
Sp1 binding in the ME promoter but it remains to be determined whether
Egr-1 or a specific Sp protein is the true accessory factor that
enhances insulin signaling through AP-1. This is a complex question
because interactions between various members of the AP-1 family and a
wide variety of structurally unrelated transcription factors have been
reported to contribute to the functional specificity of AP-1 (42),
suggesting that the action of many of these accessory factors may be
manifest in the absence of direct contact between the accessory
proteins and AP-1, although the latter do exist (43, 44).
Interestingly, Barroso and Santisteban (18) showed that overexpression
of Egr-1 actually represses basal ME-CAT fusion gene expression in H-35 hepatoma cells; we have also observed Egr-1 repression of basal ME-CAT
gene expression in H4IIE hepatoma cells but not in HeLa cells.2 The physiological significance of such an action of
Egr-1 is unclear given that insulin stimulates both ME and Egr-1 gene
expression. However, these results may imply that it is the loss of Sp
binding that explains why deletion of the ME promoter region located
between 180 and 151 reduces the stimulation of ME-CAT fusion gene
expression by insulin in H4IIE cells (16). A further complication stems from studies on the insulin-stimulated expression of calmodulin (45,
46) and apolipoprotein A-1 (47) gene expression, which suggests that
Sp1 could act directly as an insulin response factor rather than just
as an accessory factor that enhances insulin signaling through the AP-1 motif.
Although experiments in rat H4IIE hepatoma cells have implicated the ME
AP-1 motif as the target of insulin signaling (16), recent studies in
mice have suggested that a SREBP may be involved in the stimulation of
ME gene transcription by insulin in vivo. The SREBPs are
unusual transcription factors that are released from the endoplasmic
reticulum by proteolytic cleavage (48). ME gene expression is increased
in mice overexpressing SREBP-1a, SREBP-1c, or SREBP-2 (49), whereas the
induction of ME gene expression by high carbohydrate feeding, a
manipulation associated with elevated insulin levels, is abolished in
SREBP-1 (50) and SREBP-1c (51) knockout mice. Insulin selectively
induces the expression of SREBP-1c (52) but, through the stimulation of the MAP kinase pathway, might also activate SREBP-1a and SREBP-2 (53).
SREBP-1c has also been implicated in the induction of pyruvate kinase
and fatty acid synthase gene expression by glucose (13), although this
may represent an indirect effect of SREBP-1c on glucose flux, resulting
from its stimulation of glucokinase gene expression (54). This
potential connection between SREBP-1c and glucose-regulated gene
expression is interesting because there is some controversy as to the
exact relationship between insulin and glucose in the stimulation of ME
gene expression (55-57). One report suggests that insulin has little
or no direct effect but has a permissive action on the response to
glucose (55). By contrast, other investigators have reported that
insulin has a direct effect in the absence of glucose (56, 57).
Clearly, it will be of interest to delineate the relative contributions of insulin, glucose, AP-1, and SREBP in the regulation of ME gene expression in vivo.
 |
ACKNOWLEDGEMENTS |
We thank Cyrus C. Martin for useful comments
on the manuscript and Howard Towle and Jonathan Whittaker for providing
the pCAT(An) and insulin receptor expression vectors, respectively.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health (NIH) Grant DK52820 (to R. O'B.) and NIH Grant P60 DK20593, which supports the Vanderbilt Diabetes Core laboratory Grant P60 DK20593. Data analysis was performed in part through the use of the
Vanderbilt University Medical Center Cell Imaging Resource, which is
supported by NIH Grants CA68485 and DK20593.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Supported by Vanderbilt Molecular Endocrinology Training Program
Grant 5T 32 DK07563-12.
§
To whom correspondence should be addressed: Dept. of Molecular
Physiology and Biophysics, 761 PRB, Vanderbilt University Medical School, Nashville, TN 37232-0615. Tel.: 615-936-1503; Fax:
615-322-7236; E-mail: richard.obrien@mcmail.vanderbilt.edu.
Published, JBC Papers in Press, May 24, 2002, DOI 10.1074/jbc.M203682200
2
J. Ayala and R. O'Brien, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
IRS/IRE, insulin
response sequence/element;
ME, malic enzyme;
CAT, chloramphenicol
acetyltransferase;
AP-1, activator protein-1;
SRE, serum response
element;
SREBP, sterol response element-binding protein;
PMA, phorbol
12-myristate 13-acetate;
TK, thymidine kinase.
 |
REFERENCES |
| 1.
|
O'Brien, R. M.,
and Granner, D. K.
(1996)
Physiol. Rev.
76,
1109-1161[Abstract/Free Full Text]
|
| 2.
|
O'Brien, R. M.,
and Granner, D. K.
(2000)
in
Diabetes Mellitus. A Fundamental and Clinical Text
(LeRoith, D.
, Taylor, S. I.
, and Olefsky, J. M., eds), 2nd Ed.
, pp. 291-305, Lippincott-Raven, Philadelphia
|
| 3.
|
Daniel, P. B.,
Walker, W. H.,
and Habener, J. F.
(1998)
Annu. Rev. Nutr.
18,
353-383[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Rahmsdorf, H. J.,
and Herrlich, P.
(1990)
Pharmacol. Ther.
48,
157-188[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Durham, S. K.,
Suwanichkul, A.,
Scheimann, A. O.,
Yee, D.,
Jackson, J. G.,
Barr, F. G.,
and Powell, D. R.
(1999)
Endocrinology
140,
3140-3146[Abstract/Free Full Text]
|
| 6.
|
Guo, S.,
Rena, G.,
Cichy, S., He, X.,
Cohen, P.,
and Unterman, T.
(1999)
J. Biol. Chem.
274,
17184-17192[Abstract/Free Full Text]
|
| 7.
|
Hall, R. K.,
Yamasaki, T.,
Kucera, T.,
O'Brien, R. M.,
and Granner, D. K.
(2000)
J. Biol. Chem.
275,
30169-30175[Abstract/Free Full Text]
|
| 8.
|
Karin, M.,
Liu, Z.,
and Zandi, E.
(1997)
Curr. Opin. Cell Biol.
9,
240-246[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Treisman, R.
(1995)
EMBO J.
14,
4905-4913[Medline]
[Order article via Infotrieve]
|
| 10.
|
Wasylyk, B.,
Hahn, S. L.,
and Giovane, A.
(1993)
Eur. J. Biochem.
211,
7-18[Medline]
[Order article via Infotrieve]
|
| 11.
|
Ortiz, L.,
Zannini, M., Di,
Lauro, R.,
and Santisteban, P.
(1997)
J. Biol. Chem.
272,
23334-23339[Abstract/Free Full Text]
|
| 12.
|
Miyazaki, A.,
Shimura, H.,
Endo, T.,
Haraguchi, K.,
and Onaya, T.
(1999)
Endocrinology
140,
4214-4220[Abstract/Free Full Text]
|
| 13.
|
Foretz, M.,
Pacot, C.,
Dugail, I.,
Lemarchand, P.,
Guichard, C., Le,
Liepvre, X.,
Berthelier-Lubrano, C.,
Spiegelman, B.,
Kim, J. B.,
Ferre, P.,
and Foufelle, F.
(1999)
Mol. Cell. Biol.
19,
3760-3768[Abstract/Free Full Text]
|
| 14.
|
Rutter, G. A.,
White, M. R.,
and Tavare, J. M.
(1995)
Curr. Biol.
5,
890-899[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Choi, B. H.,
Park, C. J.,
and Rho, H. M.
(1998)
DNA Cell Biol.
17,
951-956[Medline]
[Order article via Infotrieve]
|
| 16.
|
Streeper, R. S.,
Chapman, S. C.,
Ayala, J. E.,
Svitek, C. A.,
Goldman, J. K.,
Cave, A.,
and O'Brien, R. M.
(1998)
Mol. Endocrinol.
12,
1778-1791[Abstract/Free Full Text]
|
| 17.
|
Chapman, S. C.,
Ayala, J. E.,
Streeper, R. S.,
Culbert, A. A.,
Eaton, E. M.,
Svitek, C. A.,
Goldman, J. K.,
Tavare, J. M.,
and O'Brien, R. M.
(1999)
J. Biol. Chem.
274,
18625-18634[Abstract/Free Full Text]
|
| 18.
|
Barroso, I.,
and Santisteban, P.
(1999)
J. Biol. Chem.
274,
17997-18004[Abstract/Free Full Text]
|
| 19.
|
Griffiths, M. R.,
Black, E. J.,
Culbert, A. A.,
Dickens, M.,
Shaw, P. E.,
Gillespie, D. A.,
and Tavare, J. M.
(1998)
Biochem. J.
335,
19-26[Medline]
[Order article via Infotrieve]
|
| 20.
|
Mamounas, M.,
Ross, S.,
Luong, C. L.,
Brown, E.,
Coulter, K.,
Carroll, G.,
and Englesberg, E.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
3530-3534[Abstract/Free Full Text]
|
| 21.
|
Mohn, K. L.,
Laz, T. M.,
Melby, A. E.,
and Taub, R.
(1990)
J. Biol. Chem.
265,
21914-21921[Abstract/Free Full Text]
|
| 22.
|
Miller, B. S.,
Shankavaram, U. T.,
Horney, M. J.,
Gore, A. C.,
Kurtz, D. T.,
and Rosenzweig, S. A.
(1996)
Biochemistry
35,
8769-8775[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Luckow, B.,
and Schutz, G.
(1987)
Nucleic Acids Res.
15,
5490[Free Full Text]
|
| 24.
|
Sudhof, T. C.,
Russell, D. W.,
Brown, M. S.,
and Goldstein, J. L.
(1987)
Cell
48,
1061-1069[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Higuchi, R.,
Krummel, B.,
and Saiki, R. K.
(1988)
Nucleic Acids Res.
16,
7351-7367[Abstract/Free Full Text]
|
| 26.
|
Streeper, R. S.,
Eaton, E. M.,
Ebert, D. H.,
Chapman, S. C.,
Svitek, C. A.,
and O'Brien, R. M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9208-9213[Abstract/Free Full Text]
|
| 27.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, E. F.
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
|
| 28.
|
Shapiro, D. J.,
Sharp, P. A.,
Wahli, W. W.,
and Keller, M. J.
(1988)
DNA (NY)
7,
47-55
|
| 29.
|
Schreiber, E.,
Matthias, P.,
Muller, M. M.,
and Schaffner, W.
(1988)
EMBO J.
7,
4221-4229[Medline]
[Order article via Infotrieve]
|
| 30.
|
Fry, C. J.,
and Farnham, P. J.
(1999)
J. Biol. Chem.
274,
29583-29586[Free Full Text]
|
| 31.
|
Buttice, G.,
Quinones, S.,
and Kurkinen, M.
(1991)
Nucleic Acids Res.
19,
3723-3731[Abstract/Free Full Text]
|
| 32.
|
Timmers, H. T.,
Pronk, G. J.,
Bos, J. L.,
and van der Eb, A. J.
(1990)
Nucleic Acids Res.
18,
23-34[Abstract/Free Full Text]
|
| 33.
|
Xia, C. L.,
Cowell, I. G.,
Dixon, K. H.,
Pemble, S. E.,
Ketterer, B.,
and Taylor, J. B.
(1991)
Biochem. Biophys. Res. Commun.
176,
233-240[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Morrow, C. S.,
Goldsmith, M. E.,
and Cowan, K. H.
(1990)
Gene (Amst.)
88,
215-225[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Tu, Z.,
and Anders, M. W.
(1997)
Biochem. Biophys. Res. Commun.
238,
285-288[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Deutsch, P. J.,
Hoeffler, J. P.,
Jameson, J. L.,
and Habener, J. F.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
7922-7926[Abstract/Free Full Text]
|
| 37.
|
Ryseck, R. P.,
and Bravo, R.
(1991)
Oncogene
6,
533-542[Medline]
[Order article via Infotrieve]
|
| 38.
|
Lefstin, J. A.,
and Yamamoto, K. R.
(1998)
Nature
392,
885-888[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Andrews, N. C.,
and Faller, D. V.
(1991)
Nucleic Acids Res.
19,
2499[Free Full Text]
|
| 40.
|
Marzluff, W. F.
(1990)
Methods Enzymol.
181,
30-36[Medline]
[Order article via Infotrieve]
|
| 41.
|
Liu, C.,
Calogero, A.,
Ragona, G.,
Adamson, E.,
and Mercola, D.
(1996)
Crit. Rev. Oncog.
7,
101-125[Medline]
[Order article via Infotrieve]
|
| 42.
|
Chinenov, Y.,
and Kerppola, T. K.
(2001)
Oncogene
20,
2438-2452[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Miner, J. N.,
and Yamamoto, K. R.
(1992)
Genes Dev.
6,
2491-2501[Abstract/Free Full Text]
|
| 44.
|
Bassuk, A. G.,
and Leiden, J. M.
(1995)
Immunity
3,
223-237[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Solomon, S. S.,
Palazzolo, M. R.,
Takahashi, T.,
and Raghow, R.
(1997)
Endocrinology
138,
5052-5054[Abstract/Free Full Text]
|
| 46.
|
Pan, X.,
Solomon, S. S.,
Borromeo, D. M.,
Martinez-Hernandez, A.,
and Raghow, R.
(2001)
Endocrinology
142,
1635-1642[Abstract/Free Full Text]
|
| 47.
|
Zheng, X. L.,
Matsubara, S.,
Diao, C.,
Hollenberg, M. D.,
and Wong, N. C.
(2000)
J. Biol. Chem.
275,
31747-31754[Abstract/Free Full Text]
|
| 48.
|
Brown, M. S.,
and Goldstein, J. L.
(1997)
Cell
89,
331-340[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Shimomura, I.,
Shimano, H.,
Korn, B. S.,
Bashmakov, Y.,
and Horton, J. D.
(1998)
J. Biol. Chem.
273,
35299-35306[Abstract/Free Full Text]
|
| 50.
|
Shimano, H.,
Yahagi, N.,
Amemiya-Kudo, M.,
Hasty, A. H.,
Osuga, J.,
Tamura, Y.,
Shionoiri, F.,
Iizuka, Y.,
Ohashi, K.,
Harada, K.,
Gotoda, T.,
Ishibashi, S.,
and Yamada, N.
(1999)
J. Biol. Chem.
274,
35832-35839[Abstract/Free Full Text]
|
| 51.
|
Liang, G.,
Yang, J.,
Horton, J. D.,
Hammer, R. E.,
Goldstein, J. L.,
and Brown, M. S.
(2002)
J. Biol. Chem.
277,
9520-9528[Abstract/Free Full Text]
|
| 52.
|
Shimomura, I.,
Bashmakov, Y.,
Ikemoto, S.,
Horton, J. D.,
Brown, M. S.,
and Goldstein, J. L.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
13656-13661[Abstract/Free Full Text]
|
| 53.
|
Kotzka, J.,
Muller-Wieland, D.,
Roth, G.,
Kremer, L.,
Munck, M.,
Schurmann, S.,
Knebel, B.,
and Krone, W.
(2000)
J. Lipid Res.
41,
99-108[Abstract/Free Full Text]
|
| 54.
|
Foretz, M.,
Guichard, C.,
Ferre, P.,
and Foufelle, F.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
12737-12742[Abstract/Free Full Text]
|
| 55.
|
Mariash, C. N.,
McSwigan, C. R.,
Towle, H. C.,
Schwartz, H. L.,
and Oppenheimer, J. H.
(1981)
J. Clin. Invest.
68,
1485-1490[Medline]
[Order article via Infotrieve]
|
| 56.
|
Spence, J. T.,
and Pitot, H. C.
(1982)
Eur. J. Biochem.
128,
15-20[Medline]
[Order article via Infotrieve]
|
| 57.
|
Garcia-Jimenez, C.,
Hernandez, A.,
Obregon, M. J.,
and Santisteban, P.
(1993)
Endocrinology
132,
1537-1543[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. M. Shewchuk, Y. Ho, S. A. Liebhaber, and N. E. Cooke
A Single Base Difference between Pit-1 Binding Sites at the hGH Promoter and Locus Control Region Specifies Distinct Pit-1 Conformations and Functions.
Mol. Cell. Biol.,
September 1, 2006;
26(17):
6535 - 6546.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Gutzman, D. E. Rugowski, M. D. Schroeder, J. J. Watters, and L. A. Schuler
Multiple Kinase Cascades Mediate Prolactin Signals to Activating Protein-1 in Breast Cancer Cells
Mol. Endocrinol.,
December 1, 2004;
18(12):
3064 - 3075.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|